{
    "clinical_study": {
        "@rank": "51988", 
        "arm_group": {
            "arm_group_label": "LAAM arm", 
            "arm_group_type": "Experimental", 
            "description": "[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)\nEfavirenz, oral capsules, 600 mg\nRitonavir, oral capsules, 100 mg"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effects of the antiretroviral drugs efavirenz\n      and ritonavir on human brain LAAM disposition in vivo."
        }, 
        "brief_title": "LAAM-HAART PET Imaging", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion\n\n        Each subject must meet all of the following criteria:\n\n          1. Male or non-pregnant female volunteer, 18-50 yr old\n\n          2. Good general health with no known major medical conditions\n\n          3. BMI  < 33\n\n          4. Provide informed consent\n\n        Exclusion Criteria\n\n        Subjects will not be enrolled if any of the following criteria exist:\n\n          1. Known history of liver or kidney disease\n\n          2. History of major medical conditions\n\n          3. HIV seropositive\n\n          4. Fasting blood glucose > 110 mg/dl (because HAART can cause glucose intolerance)\n\n          5. Family history of type 2 diabetes\n\n          6. Use of  prescription or non prescription medications, herbals or foods known to be\n             metabolized by or altering P-glycoprotein or CYP3A (hormonal birth control\n             medications are acceptable if alternative means of contraception are used)\n\n          7. Females who are pregnant or nursing\n\n          8. Females taking hormonal contraceptives who are unwilling to use alternative means of\n             contraception\n\n          9. Contraindications to MRI (e.g., metal implants or splinters in the body; a worn or\n             implanted medical device, such as a pacemaker or drug pump; inability to lie flat for\n             up to one hour; claustrophobia) or contraindications to PET scanning (e.g., inability\n             to lie flat for up to one hour, claustrophobia, current\n\n         10. Current or recent (within 12 months prior to screening) participation in research\n             studies involving radiation exposure such that the total research-related radiation\n             dose to the subject in any given year would exceed the limits set forth in the US\n             Code of Federal Regulations (CFR) Title 21 Section 361.1\n             (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1))"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935830", 
            "org_study_id": "201307040"
        }, 
        "intervention": [
            {
                "arm_group_label": "LAAM arm", 
                "description": "intravenous administration of 15-20 mCi of [11c] LAAM.", 
                "intervention_name": "[11c] LAAM", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "LAAM arm", 
                "description": "Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.", 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug", 
                "other_name": "Kaletra"
            }, 
            {
                "arm_group_label": "LAAM arm", 
                "description": "Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.", 
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug", 
                "other_name": "Sustiva, Atripla"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir", 
                "Efavirenz", 
                "Methadyl Acetate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PET Imaging", 
            "Efavirenz", 
            "Ritonavior [11C] LAAM", 
            "Healthy volunteers"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Evan D Kharasch, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging", 
        "overall_contact": {
            "email": "freyk@anest.wustl.edu", 
            "last_name": "Karen Frey", 
            "phone": "314-5980"
        }, 
        "overall_contact_backup": {
            "email": "bloodj@anestwustl.edu", 
            "last_name": "Jane Blood, RN", 
            "phone": "314-747-5531"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Evan D Kharasch, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood tests, MRI and PET data analysis and interpretation", 
            "measure": "cerebral [11C]LAAM distribution volume", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}